The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
RD - yes, I'd be interested.
A similar thing was done for 88 Energy (88E) investors- a small oil exploration currently involved on the North Alaskan Slope. Regrettably the SP crashed recently and I still shudder at losses on my smallish investment.
But the facility set up and maintained by a couple of investors there is a very useful resource with ooodles of information there :
http://88ewiki.wikidot.com
Thanks Trek for your most interesting discussion (with references) about digitisation of LFD's. I had no idea of this sort of thing & learned a lot! I admit I will have to read your post + the refs again with a fresh mind tmoz!! Just enjoyed a nice take-away meal with the Mrs this evening with too much good Rioja so my mental state is not in top form at the moment. I'll sleep well tonight dreaming of Avacta SP in 2 months.
Thx again.
Flyingmachine - thanks for your take on this. You make sensible and realistic comments, and I say that without in any way trying to appear patronising.
I simply hope that end-user sample collection does not compromise our progress in any way whatsoever, whatever is decided.
Thanks to those who responded to the questions!
If the LFD is going to be marketed directly to end users, and that seems to be the case, rest assured that regulatory authorities will take great interest in checking out the propensity for end user errors that might give rise to an incorrect result.
Hence the reason for my posing the question about the process of sample collection.
The video about the Oratect slide was interesting and although this slide is more complex in that it tests for multiple analytes, there is obviously plenty that can go wrong and the commentary simply keeps saying if the checks and balances at any stage indicate it's not working the test slide in use should be discarded and a new one tried again.
It is unlikely that say at £25 a go, an end user will have an unlimited supply of slides to keep trying until they get it right and so will be very tempted to simply to "make do".
I will be very interested to see what the approach of Avacta/Cytiva is to this seemingly simple side of things - it is a pity there is no opportunity for us to ask Alastair about this.
I imagine that Avacta will have the answers to these 2 questions - if so, I'm not aware of them. Is anybody here?
1. How does the saliva get on to the test area on the strip? Does it involve the use of buffer solutions into which the sample of saliva is added? Is more equipment supplied with the slide e.g. some sort of sample collection device or container? Is mouth preparation necessary before acquiring the sample e.g. mouth rinsing in with water?
I only ask because such steps add to the complexity of using the test, and to the possibility of errors - leading at worst to false negatives.
2. As the LFD is to be supplied direct to the end-user is there an obligation for that person to inform the appropriate health body - for public health purposes? This seems to me to be quite important, especially for a possible result.
Possibly a "free-for-all" unrestricted use of the procedure for the UK at least, and perhaps for many/most countries, could mean that its use might be discouraged.
What do you think?
Thank you for that metis20. You've forced me to open a bottle of my favourite Stroud Brewery "Budding" and it's only on very special occasions I have a drink before lunch. I wish I was as careful as you at reading RNS's!
Some great posts here this morning. Thanks all.
https://avacta.com/how-a-lateral-flow-rapid-test-works/
So here is that reminder from Alastair as to how an affimer lateral flow test works.
Only posting to say, if I may, how much I agree with you Ophidian. Will be interested to see the results of your calculations in due course. Some idea of likely sensitivity would be great - that is the final decider now. Thanks.
Thanks to you as well PL75 - post of the day IMO!
Took about 3 minutes to get registered on-line, but then came up with Offer Closed.
Oh well! Took just over 2 hours then.
Bodes well. Holding the bulk of my AVCT lot in an ISA - long, and strong. Happy to stay for the duration.
GLA
Fair comment LordSutch.
I have used charting a lot for FTSE350 stocks and find it very helpful. I think its value is much less use for lower cap news-driven AIM stocks but I still look at the up-to-date-chart (Sharescope) before trading any LSE quoted stock.
I use candlestick signals a great deal, and to all those who may now pop here saying this is all mumbo-jumbo I will just ignore you - so don't waste your time!!
The reason for posting this (I rarely do highlight chart signals on BB's) is that after today's extraordinary AVCT price movements there is a really good example today of a "bullish reversal pattern".
The signal is "a hammer", discussion of which attracts about 10 pages of discussion in the "Reversal Pattern" chapter in Steve Nison's classic treatise "Japanese Candlestick Charting Techniques".
You can see a summary of the characteristic features here:
h t t p s://www. i n v e s topedia.com/articles/active-trading/062315/using-bullish-candlestick-patterns-buy-stocks.asp#1-the-hammer-or-the-inverted-hammer (delete the spaces)
Today's AVCT chart shows a classic hammer (as good an example as you will see) on high daily volume (the highest for 28 trading days). Also it has has occurred in a decent downtrend - for the last 5 trading days - as we are all aware.
-
The best take on this is to use it as a reversal SIGNAL. A rise tomorrow will indicate CONFRIMATION of that signal, and constitute a strong bullish indicator.
I do emphasise that these signals (and any TA signal), although potent, are not 100% reliable. But I have learned, on average, to ignore them at your peril!
The "metatrade" buys and sells (implied by which side of the midprice the deal prices sits) are not worth wasting your time on. When prices are falling relentlessly there are more sellers than buyers. Simples!
Happy that you agree RichKen.
What I will say is that the well known aphorism "travelling can be better than arriving" may well hold here for sure. A n RNS simply saying "Acvt and (a big pharma) have agreed to cooperate to develop neutralising therapy" would be a huge boost, and such an RNS could well land at any time!